drugset / Trial / NCT04510311
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.
Timeline
- Start
- 2020-10-19
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | 123I-mIBG | Diagnostic / imaging agent | 370 mbq | Intravenous |
| Subject | [18F]3F-PHPG | Unknown | 444 mbq | Intravenous |